LONDON and PHILADELPHIA, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Avacta said on Thursday it had agreed the design of a pivotal US trial for its lead cancer therapy with the US Food and Drug ...
(Reuters) -Britain's Avacta Group is halting sales of its COVID-19 rapid antigen lateral flow test to replace antibodies in the device and boost its ability to detect the Omicron variant, the biotech ...
14d
Avacta Strengthens Funding Position as pre|CISION Oncology Programmes Reach Key Milestones (AVCT)
Avacta Group plc (LSE:AVCT) has reported significant progress across its oncology portfolio during 2026, advancing multiple ...
Multiple confirmed partial and minor responses observed in patients with SGC Continuing very good safety profile, with removal of the lifetime maximum doxorubicin limit based on highly favorable ...
(MENAFN- GlobeNewsWire - Nasdaq) Encouraging Progression Free Survival (PFS) data observed in patients with salivary gland cancers compared to conventional treatments LONDON and PHILADELPHIA, March 07 ...
LONDON – Oct. 21, 2024 – Avacta Therapeutics (AIM: AVCT), a life sciences company developing next generation peptide drug conjugates (PDC) targeting powerful anti-tumor payloads directly to the tumor, ...
"The data with our pre|CISION technology to deliver dual payloads has now demonstrated for the first time an efficacy advantage over single payload ADCs in a FAP-low and HER2-positive patient-derived ...
Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, and Daewoong Pharmaceutical Co. Ltd., a leading Korean pharmaceutical company, are pleased to announce that they have agreed ...
Avacta Group plc, the developer of Affimer ® biotherapeutics and reagents, is pleased to announce that it has entered into an exclusive distribution agreement with Medusa19 Limited (“Medusa19”) for ...
Avacta to replace antibodies in AffiDX test Finds test is less sensitive to Omicron at lower viral loads No timeline for sales resumption, shares plunge 26.5% Jan 10 (Reuters) - Britain's Avacta Group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results